RU2247557C2 - Фармацевтические композиции, включающие циклические глицерофосфаты и их аналоги, для активации дифференцировки нервных клеток - Google Patents

Фармацевтические композиции, включающие циклические глицерофосфаты и их аналоги, для активации дифференцировки нервных клеток Download PDF

Info

Publication number
RU2247557C2
RU2247557C2 RU2001128743/15A RU2001128743A RU2247557C2 RU 2247557 C2 RU2247557 C2 RU 2247557C2 RU 2001128743/15 A RU2001128743/15 A RU 2001128743/15A RU 2001128743 A RU2001128743 A RU 2001128743A RU 2247557 C2 RU2247557 C2 RU 2247557C2
Authority
RU
Russia
Prior art keywords
cyclic
cgp
diseases
disorders
phenyl
Prior art date
Application number
RU2001128743/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2001128743A (ru
Inventor
Мейр ШИНИЦКИЙ (IL)
Мейр Шиницкий
Original Assignee
Йеда Рисерч Энд Дивелопмент Ко.Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йеда Рисерч Энд Дивелопмент Ко.Лтд. filed Critical Йеда Рисерч Энд Дивелопмент Ко.Лтд.
Publication of RU2001128743A publication Critical patent/RU2001128743A/ru
Application granted granted Critical
Publication of RU2247557C2 publication Critical patent/RU2247557C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
RU2001128743/15A 1999-03-25 2000-03-24 Фармацевтические композиции, включающие циклические глицерофосфаты и их аналоги, для активации дифференцировки нервных клеток RU2247557C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL129178 1999-03-25
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation

Publications (2)

Publication Number Publication Date
RU2001128743A RU2001128743A (ru) 2003-07-10
RU2247557C2 true RU2247557C2 (ru) 2005-03-10

Family

ID=11072645

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001128743/15A RU2247557C2 (ru) 1999-03-25 2000-03-24 Фармацевтические композиции, включающие циклические глицерофосфаты и их аналоги, для активации дифференцировки нервных клеток

Country Status (16)

Country Link
US (1) US6914056B1 (enExample)
EP (1) EP1162959B1 (enExample)
JP (1) JP2002540146A (enExample)
KR (1) KR20010112364A (enExample)
CN (1) CN1348375A (enExample)
AT (1) ATE290385T1 (enExample)
AU (1) AU768911B2 (enExample)
BR (1) BR0009296A (enExample)
CA (1) CA2368597A1 (enExample)
DE (1) DE60018554T2 (enExample)
HK (1) HK1042038A1 (enExample)
IL (1) IL129178A0 (enExample)
MX (1) MXPA01009650A (enExample)
NZ (1) NZ514525A (enExample)
RU (1) RU2247557C2 (enExample)
WO (1) WO2000057865A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253918T1 (de) 1999-12-08 2003-11-15 Centre Nat Rech Scient Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
JP4815063B2 (ja) * 2001-04-13 2011-11-16 きみ子 室伏 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
IL148665A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants
IL148668A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
EP1511483A4 (en) * 2002-03-27 2009-03-18 Smithkline Beecham Corp PROCESSING METHODS USING LXR MODULATORS
JP4162927B2 (ja) 2002-06-11 2008-10-08 きみ子 室伏 カルバ環状ホスファチジン酸誘導体
US8101552B2 (en) * 2005-03-14 2012-01-24 Yeda Research And Development Company Ltd. Cyclic phosphates as plant growth regulators
NZ571975A (en) * 2006-04-26 2011-04-29 Toyama Chemical Co Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising benzothiopene alkyl ether derivative or salt thereof
EP2098237B1 (en) * 2006-12-28 2012-08-29 Ochanomizu University Analgesic agent comprising cyclic phosphatidic acid derivative
WO2010080969A1 (en) * 2009-01-09 2010-07-15 Sigma-Aldrich Co. Process for the synthesis of beta glycerol phosphate
WO2011065480A1 (ja) * 2009-11-26 2011-06-03 国立大学法人お茶の水女子大学 神経細胞死抑制剤
JP6007264B2 (ja) 2013-01-28 2016-10-12 国立大学法人お茶の水女子大学 脱髄疾患治療薬
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
CA3007063A1 (en) * 2015-12-08 2017-06-15 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63037A (en) * 1981-06-04 1985-12-31 Israel State Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them
JPH06228169A (ja) * 1993-02-05 1994-08-16 Sagami Chem Res Center １−ｏ−アシルグリセロール２，３−ホスフェートの製造法
JPH07149772A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center タンパク質リン酸化酵素ｃの活性促進剤
JPH07258278A (ja) * 1994-03-18 1995-10-09 Sagami Chem Res Center １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤
JPH0925235A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
IL129179A0 (en) * 1999-03-25 2000-02-17 Yeda Res & Dev Cyclic glycerophosphates and analogs thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Е.М.Хватова, и др. Нуклеотиды мозга. - М.: Медицина, 1989, с.97-131. *

Also Published As

Publication number Publication date
EP1162959B1 (en) 2005-03-09
CN1348375A (zh) 2002-05-08
US6914056B1 (en) 2005-07-05
IL129178A0 (en) 2000-02-17
DE60018554T2 (de) 2006-04-13
WO2000057865A3 (en) 2001-06-28
AU768911B2 (en) 2004-01-08
JP2002540146A (ja) 2002-11-26
NZ514525A (en) 2003-10-31
MXPA01009650A (es) 2002-07-02
BR0009296A (pt) 2001-12-18
WO2000057865A9 (en) 2001-11-15
EP1162959A2 (en) 2001-12-19
KR20010112364A (ko) 2001-12-20
AU3451700A (en) 2000-10-16
HK1042038A1 (zh) 2002-08-02
WO2000057865A2 (en) 2000-10-05
ATE290385T1 (de) 2005-03-15
DE60018554D1 (de) 2005-04-14
CA2368597A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
RU2247557C2 (ru) Фармацевтические композиции, включающие циклические глицерофосфаты и их аналоги, для активации дифференцировки нервных клеток
Feldberg Present views on the mode of action of acetylcholine in the central nervous system
EP0711559B1 (en) Use of phosphatidylserines for the manufacture of a medicament for improving cerebration
US4263286A (en) Therapeutic agent for consciousness disorder and perception and movement disorder
Morrisett et al. Biochemical evidence for enhanced sensitivity to N-methyl-D-aspartate in the hippocampal formation of kindled rats
Philippens et al. Behavioral performance, brain histology, and EEG sequela after immediate combined atropine/diazepam treatment of soman-intoxicated rats
JP2008502705A (ja) 発作および発作性障害を処置するための化合物ならびに方法
Emerich et al. Selective working memory impairments following intradentate injection of colchicine: attenuation of the behavioral but not the neuropathological effects by gangliosides GM1 and AGF2
US8017597B2 (en) Analgesic agent comprising cyclic phosphatidic acid derivative
JP2002514185A (ja) ＮＡＡＬＡＤａｓｅ阻害剤を用いる強迫性障害の治療の医薬組成物及び方法
PT1864667E (pt) Uso de pró-fármacos para administração intravítrea ocular
Einat et al. Augmentation of lithium's behavioral effect by inositol uptake inhibitors
De Cesare et al. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts
EP1455797A2 (en) Pseudopterosin compounds of symbiodinium spp isolated from pseudopterogorgia elisabethae
Pike et al. Effect of tetrahydroaminoacridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury
US20050026847A1 (en) Methods for treating, preventing, or inhibiting injuries, cell membrane stabilization, and calcium mobilization using pseudopterosin compounds
US20020058669A1 (en) Process for the treatment of organophosphate poisoning
Monastersky et al. Comparison of the neuritogenic activity of cyclic nucleotides and skeletal muscle-conditioned medium on ciliary ganglia in vitro
HONGO et al. Effects of various drugs and extrinsic denervation on the non-adrenergic inhibitory neurons in the rat stomach
US20060040901A1 (en) Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants
Capek et al. Pharmacological Symposium, Czechoslovakia Translation
Briant Actions of Drugs on Metabolic Processes in the Central Nervous System

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20060325